Now that Actavis' $66 billion Allergan buy--and the bitter takeover war between Allergan and Valeant that preceded it--are in the books, there's much to reflect on. And a lot of lingering questions about how the saga will impact dealmaking moving forward, too.
Becton Dickinson is reviewing its assets now that the $12.4 billion CareFusion deal closed last week. The $30 billion medical products and diagnostics company is expected to sell the respiratory device business that was formerly part of CareFusion, Bloomberg reports.
Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie's $21 billion buyout goes through. But considering Duggan's record, a multibillion-dollar payoff is to be expected. It's the other executives and directors--who together qualify for more than $575 million--who could inspire M&A envy.
Antech Diagnostics, the lab division of veterinary hospital chain VCA, has agreed to buy the assets of Abaxis' Veterinary Reference Laboratory for $21 million in cash.
Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.
Biotech Kite Pharma, which has become a force in cancer immunotherapy, has added some more manufacturing capabilities to the operations it has been beefing up.
Orphan drug biotech Retrophin is the new owner of an FDA-approved rare disease treatment and a potentially lucrative voucher for a future speedy review thanks to a $75 million buyout agreement.
As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?
Kite Pharma, a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.
Actavis and Allergan can finally celebrate: They've cleared the last hurdle to closing their $66 billion merger agreement.